Penumbra Q3 revenue $354.7M (+17.8% YoY); full-year guidance raised to $1.375-1.380B

Penumbra Inc

2025-Q3 EPS reported $3.32 revenue$1,018,280,000

Net income of $45.9M; adjusted EBITDA $66.7M (18.8% margin).
U.S. Thrombectomy revenue $192.0M (+18.5%); U.S. VTE revenue up 34% YoY.
Gross margin improved to 67.8% vs 66.5% a year ago; operating margin 13.8%.
Full-year 2025 revenue guidance increased to $1.375B-$1.380B (15-16% growth).
Total revenue $354.7M (+17.8% or +16.9% constant currency); U.S. revenue +21.5%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.